News & Events:HTGC

Gritstone bio Inc (GRTS): * GRITSTONE REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Gritstone bio Inc (GRTS) - QTRLY LOSS PER SHARE $0.34 Source text for Eikon: Further company coverage:

-- Clinical programs continue to progress, with initial data from Phase 2 study of “off the shelf” SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program expected this year -- -- Follow up data from subset of CORAL-BOOST study shows strong neutralizing antibody titers persisted without decay for at least 6 months after single boost administration of self-amplifying mRNA -- --...

  See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

Hercules Capital Inc (HTGC): * HERCULES CAPITAL REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS. * Hercules Capital Inc (HTGC) - QTRLY NET INVESTMENT INCOME OF $40.1 MILLION, OR $0.32 PER SHARE, AN INCREASE OF 8.6% Source text for Eikon: Further company coverage:

Record 1H 2022 Total Gross Debt and Equity Commitments of $1.66 Billion Record 1H 2022 Gross Fundings of $790.7 Million Record 1H 2022 Net Debt Investment Portfolio Growth of $359.8 Million Record Q2 Total Gross Debt and Equity Commitments of $1.04 Billion Increased the Company’s Quarterly Base Cash Distribution to $0.35 per Share Increased Available Liquidity to over $775 Million Through a Ser...

  ** ArcelorMittal is estimated to report earnings for its second quarter. ** argenx is likely to report quarterly loss at $4.83 per share on revenue of $37.85 million. ** ASE Technology Holding Co is estimated to report quarterly earnings at $0.20 per share on revenue of $5.08 billion. ** Barclays is estimated to report earnings for its second quarter.

  ** ArcelorMittal is estimated to report earnings for its second quarter. ** argenx is likely to report quarterly loss at $4.83 per share on revenue of $37.85 million. ** ASE Technology Holding Co is estimated to report quarterly earnings at $0.20 per share on revenue of $5.08 billion. ** Barclays is estimated to report earnings for its second quarter.

Hercules Capital is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Analysts estimate that Hercules Capital will report an earnings per share of $0.33. Hercules Capital bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

Here's a roundup of top developments in the biotech space over the last 24 hours: U.K.'s Medicines and Healthcare products Regulatory Agency has approved Global Blood Therapeutics Inc's  Oxbryta for hemolytic anemia due to sickle cell disease in patients 12 and above. The approval comes for Oxbryta as monotherapy or in combination with hydroxycarbamide.

IVERIC bio Shares Jump On Debt Financing To Fund Zimura Launch

IVERIC bio, Inc. (ISEE) announced today that it has entered into a term loan debt financing facility with Hercules Capital, Inc. (HTGC) and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-dilutive debt financing.

Hercules Capital Inc (HTGC): * HERCULES CAPITAL INCREASES ITS QUARTERLY CASH DISTRIBUTION TO $0.35 PER SHARE FOR THE SECOND QUARTER OF 2022 Source text for Eikon: Further company coverage:

The Supplemental Cash Distribution of $0.15 per Share is in Addition to the Regular Quarterly Cash Distribution for the Second Quarter of 2022 of $0.35 per Share Hercules Capital, Inc. (HTGC), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is p...

Hercules Capital, Inc. (HTGC), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has increased and declared a second quarter 2022 cash distribution of $0.35 per share.

Gritstone bio, Inc. (GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced it has entered into an $80 million credit facility with Hercules Capital, Inc. (HTGC) and Silicon Valley Bank.

Hercules Capital, Inc. (HTGC), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2022 financial results conference call for Thursday, July 28, 2022, at 2:00 p.m. PT.

Up to $50 Million in Additional Non-Dilutive Capital Potentially Available in 2023 Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced an amendment to expand its existing loan facility with Hercules Capital, Inc. (HTGC) and Silicon Valley Bank, from up to $75 million to up to $125 million.

Analysts have provided the following ratings for Hercules Capital within the last quarter: These 4 analysts have an average price target of $17.88 versus the current price of Hercules Capital at $13.915, implying upside. Below is a summary of how these 4 analysts rated Hercules Capital over the past 3 months.

Hercules Capital Inc (HTGC): * HERCULES CAPITAL ANNOUNCES THE APPOINTMENT OF MS. DEANNE AGUIRRE TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Hercules Capital, Inc. (HTGC), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022.